{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:52:40Z","timestamp":1776750760841,"version":"3.51.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172700"],"award-info":[{"award-number":["82172700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300420111"],"award-info":[{"award-number":["252300420111"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucosal melanomas arise from melanocytes in mucosal tissues, and it\u2019s usually detected at a late stage owing to its anatomic location. Advances in immunotherapies have proved to be promising therapeutic approaches for advanced mucosal melanoma patients, however, clinical studies have shown mucosal melanoma patients are less responsive to ICIs than cutaneous melanoma. Effective therapy is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of SHR-1210 (an anti-programmed cell death-1 antibody) in combination with Apatinib (a vascular endothelial growth factor receptor 2 inhibitor) as late-line treatment in patients with advanced mucosal melanoma (Ethics approval number 2019184;ClinicalTrials.gov ID: NCT03986515).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Patients with confirmed metastatic mucosal melanoma according to AJCC 8.0. In this single-arm, single-center, phase II nonrandomized clinical trial, patients with advanced mucosal melanoma who have received several line treatments were enrolled between 2019.06 and 2022.12. The data cutoff date was June 11th, 2025. Patients received 200mg SHR-1210 intravenously every 3 weeks, and oral Apatinib 250 mg daily until unacceptable toxic effects or disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 13 patients were enrolled and received treatment. The disease control rate (DCR) reached 100% (SD\u00a0=\u00a013). The objective response rate (ORR) was 0%. The estimated median overall survival (OS) was 29.9 months (95% CI 15.26-44.54),. The estimated median progression-free survival (PFS) was 5.17 months (95% CI 3.27-10.27),. The most common grade 1\u20132 was hand and foot induration with desquamation and pain, and one case of grade 4 abnormal liver function and grade 3 hypertension. No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This suggests that this combination therapy model may be a promising disease control for mucosal melanomas. However, the sample size is relatively small and needs to be increased for further research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT03986515<\/jats:ext-link>\n                      , identifier NCT03986515.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1755669","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:48Z","timestamp":1776749628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine"],"prefix":"10.3389","volume":"17","author":[{"given":"Yong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Qi","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Di","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Bing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Man","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Zhen","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qun","family":"Dong","sequence":"additional","affiliation":[{"name":"Precision Health Program, Department of Radiology, College of Human Medicine, Michigan State University","place":["East Lansing, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan-Li","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01453-x","article-title":"Mucosal melanoma: epidemiology, clinical features, and treatment","volume":"25","author":"Sergi","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1358\/dnp.2000.13.2.858467","article-title":"Melanoma","volume":"1","author":"SChadendorf","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02351-7","article-title":"Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma","volume":"68","author":"Moya-Plana","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009662","article-title":"Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial","volume":"12","author":"Tang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-17-2176","article-title":"Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004036","article-title":"Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis","volume":"10","author":"Li","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2021.07.018","article-title":"Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma","volume":"156","author":"Tang","year":"2021","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.12.027","article-title":"Apatinib combined with camrelizumab in advanced acral melanoma patients: an open-label, single-arm phase 2 trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23606","article-title":"Molecular profiling and tumor microenvironment in sinonasal mucosal melanoma as biomarkers for enhanced prognostic stratification","volume":"15","author":"Molina-Garcia","year":"2025","journal-title":"Int Forum Allergy Rhinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008611","article-title":"Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma","volume":"12","author":"Zhao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.07.009","article-title":"Safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure","volume":"11","author":"Cui","year":"2018","journal-title":"Transl Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1528","article-title":"Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study","volume":"28","author":"Mao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G(4) monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14712598.2025.2557625","article-title":"Combining VEGF and PD-1\/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions","volume":"25","author":"Balsano","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2024.103700","article-title":"Fruquintinib combined with PD-1 inhibitors for the treatment of the patients with microsatellite stability metastatic colorectal cancer: real-world data","volume":"38","author":"He","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.014","article-title":"Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer","volume":"35","author":"Di Federico","year":"2024","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105315","article-title":"Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy","volume":"10","author":"Sharma","year":"2025","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111151","article-title":"Inhibition of angiogenesis and metastasis in colorectal cancer cell lines through KRAS-associated signaling pathways by 2-methoxy-6-undecyl-1,4-benzoquinone","volume":"399","author":"Abd Rahman","year":"2024","journal-title":"Chem Biol Interact"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1755669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:33:48Z","timestamp":1776749628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1755669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1755669"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1755669","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1755669"}}